Browse articles from EyeWorld.org related to dry eye. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ First patient treated in Phase 2 study of investigational emulsion for glaucoma ➤ FDA issues complete response letter for dry eye drug NDA ➤ FDA meeting minutes issued for BLA submissions of ophthalmic formulation of bevacizumab ➤ Phase 1/2 trial to begin for first-in-class dry AMD therapy ➤ Company merger news ➤ ASCRS news and events
➤ 3-year efficacy and safety results of gene therapy for wet AMD reported ➤ Phase 2 trial results of gene therapy for diabetic retinopathy ➤ Phase 2 program for tracking glaucoma biomarkers begins ➤ Results from extension study of the first approved treatment for geographic atrophy ➤ Primary endpoint agreed upon for investigational oral diabetic retinopathy therapy ➤ ASCRS news and events
➤ Editorial statement on the nomenclature for refractive lenticule extraction procedure ➤ First patient dosed in Phase 1/2 trial evaluating allogenic cell therapy for corneal edema ➤ IND granted to company investigating therapy for geographic atrophy ➤ Licensing agreement to develop neuroprotective drug ➤ Retinal imaging test detects increased risk for type of dementia ➤ ASCRS news and events
➤ FDA approves presbyopia drop ➤ FDA approves expanded capabilities on anterior segment diagnostic platform ➤ Phase 4 data presented for dry eye disease drug ➤ Extension study for investigational wet AMD treatment demonstrates safety, efficacy ➤ Reports suggest reproxalap NDA might not be approved ➤ Companies partner to develop gene therapy ➤ ASCRS news and events
➤ Study: large-scale MIGS study ➤ Partnership to advance early disease detection ➤ License agreement to move forward option for cataract surgery sedation ➤ Name change news ➤ ASCRS news and events
➤ FDA issues eight warning letters ➤ Positive Phase 2 safety update for investigational treatment of retinal diseases ➤ First-in-human titratable glaucoma therapy system ➤ Companies partner to develop biological dry eye treatment ➤ Geographic atrophy drug development discontinued ➤ ASCRS news and events
➤ Study: 1-year results with IOP-lowering implant ➤ Phase 2 study of investigational dry eye treatment nears enrollment target ➤ Study identifies antibody that could lead to retinitis pigmentosa treatment ➤ Gene therapy for inherited optic neuropathy approved for clinical trials ➤ ASCRS news and events
➤ FDA approves first treatment targeting Demodex ➤ Phase 1 study compares mechanical dry eye treatment to drop therapy ➤ Topical gene therapy for rare ocular surface condition ➤ Glaucoma drug licensed for commercialization in U.S. ➤ ASCRS news and events
This article recaps the 2023 Richard L. Lindstrom, MD, Lecture, titled “Glaucoma Surgery: Taking it to the Next Level,” given by Marlene Moster, MD, as well as the other presentations in the session, given by Cathleen McCabe, MD, Francis Mah, MD, and Daniel Chang, MD.
➤ Results from Phase 2a study evaluating glaucoma drop ➤ Enrollment complete for epi-on crosslinking trial ➤ Phase 2 clinical trial begins for investigational dry eye drop ➤ Enrollment complete for Phase 2 study to evaluate diabetic retinopathy treatment ➤ Phase 2b trial for wet AMD treatment begins enrollment ➤ ASCRS news and events